{"product_id":"ace-083","title":"ACE-083","description":"\u003ch3\u003ePharmacokinetics\u003c\/h3\u003e\nACE-083 is a synthetically engineered ligand trap, and works primarily by blocking signals that inhibit muscular growth.[2] Within the body, there are proteins that restrict muscle gain, called myostatins. In the absence of ACE-083, myostatins block chemical signals that lead to muscle growth. When administered, ACE-083 binds to the myostatins. This binding results in uninhibited muscle growth.[3]\u003cbr\u003e \u003cbr data-mce-fragment=\"1\"\u003e\n\u003ch3\u003eScientific Studies\u003c\/h3\u003e\nThere have been multiple human and animal studies of ACE-083, pointing towards a correlation between its administration and local muscle growth. In one animal study, subjects were injected with ACE-083 twice per week, over four weeks. Findings indicated muscle growth localized to the site of injection.[2] Another study conducted on postmenopausal women provided similar findings. All 42 non-placebo subjects appeared to demonstrate higher muscle volume where ACE-083 was injected.[4] Both of these studies show that this peptide may promote higher rates of muscle growth.\u003cbr\u003e \u003cbr data-mce-fragment=\"1\"\u003e\n\u003ch3\u003eSources:\u003c\/h3\u003e\n[1] https:\/\/strongly.mda.org\/fda-grants-orphan-drug-designation-to-acceleron-pharmas-ace-083-muscle-growth-drug-for-charcot-marie-tooth-disease\/\u003cbr data-mce-fragment=\"1\"\u003e\u003cbr data-mce-fragment=\"1\"\u003e[2] https:\/\/www.nmd-journal.com\/article\/S0960-8966(15)00304-1\/abstract\u003cbr data-mce-fragment=\"1\"\u003e\u003cbr data-mce-fragment=\"1\"\u003e[3] https:\/\/acceleronpharma.com\/wp-content\/uploads\/2017\/03\/20141009-ACE-083-20141009-ACE-083-a-ligand-trap-for-members-of-the-TGFB-superfamily-increases-muscle-mass-loc.pdf\u003cbr data-mce-fragment=\"1\"\u003e\u003cbr data-mce-fragment=\"1\"\u003e[4] https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29486514\u003cbr data-mce-fragment=\"1\"\u003e\u003cbr data-mce-fragment=\"1\"\u003e[5] https:\/\/charcot-marie-toothnews.com\/2018\/07\/26\/preliminary-cmt-phase-2-trial-results-ace-083-presented\/","brand":"Apex Receptor","offers":[{"title":"Default Title","offer_id":45393094279215,"sku":"4495019776","price":69.99,"currency_code":"BRL","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0767\/1483\/6015\/files\/ACE-083.jpg?v=1779909963","url":"https:\/\/genurex.com\/products\/ace-083","provider":"Genurex","version":"1.0","type":"link"}